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Abstract. 
The development of novel non-viral delivery vehicles is essential in the search of more efficient 
strategies for retina and brain diseases. Herein, optimized niosome formulations prepared by 
oil-in water (o/w) and film-hydration techniques were characterized in terms of size, PDI, zeta 
potential, morphology and stability. Three ionizable glycerol-based cationic lipids containing a 
primary amine group (lipid 1), a triglycine group (lipid 2) and a dimethylamino ethyl pendent 
group (lipid 3) as polar head-groups were part of such niosomes. Upon the addition of pCMS-
EGFP plasmid, nioplexes were obtained at different cationic lipid/DNA ratios (w/w). The 
resultant nioplexes were further physicochemically characterized and evaluated to condense, 
release and protect the DNA against enzymatic digestion. In vitro experiments were performed 
to evaluate transfection efficiency and cell viability in HEK-293, ARPE-19 and PECC cells. 
Interestingly, niosome formulations based on lipid 3 showed better transfection efficiencies in 
ARPE-19 and PECC cells than the rest of cationic lipids showed in this study. In vivo 
experiments in rat retina after intravitreal and subretinal injections together with in rat brain 
after cerebral cortex administration showed promising transfection efficiencies when niosome 
formulations based on lipid 3 were used. These results provide new insights for the 
development of non-viral vectors based on cationic lipids and their applications for efficient 
delivery of genetic material to the retina and brain. 
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INTRODUCTION 
 
Gene therapy is a challenging field that is emerging as a promising strategy for the 
treatment of several diseases [1]. Concretely, non-viral vectors have attracted the interest of 
the scientific community because, compared to viral vectors, they offer a safer way to deliver 
genetic material, as they do not exhibit antigen-specific immune and inflammatory response, 
are cheaper, easy to elaborate and the size of DNA inserted is theoretically unlimited [2]. 
Nevertheless, their low transfection efficiencies and the transient gene expression are the 
main concerns that these carriers have to overcome to reach clinical practice. There is a wide 
range of non-viral vectors described in the literature, such as those composed of polymers, 
lipids or peptides [3-5]. Among lipidic systems, liposomes are the most common vectors. 
However, our research group has previously described that niosomes are a promising 
alternative to liposomes for gene delivery purposes. Niosomes are carrier systems that form 
vesicles with a bilayer structure and compared to liposomes they are recognized for their low 
cost and superior chemical and storage stabilities. Nevertheless, few reports have been 
focused on their application for gene delivery purposes [6,7]. 
Unlike liposomes, which are elaborated with phospholipids, niosomes for gene delivery 
purposes are typically based on nonionic surfactants to form more stable emulsions. In 
addition, helper lipids are also added to the formulations to enhance the physicochemical 
properties of the emulsion and finally, the cationic lipids, whose structural and physical 
properties clearly influence the transfection efficiency and toxicity [8-10].  
Cationic lipids for gene delivery purposes usually contain four functional domains 
(hydrophobic group, linker group, hydrophilic head-group and backbone), which affect some 
important physicochemical parameters, such as the flexibility, stability, biodegradability, the 
level of hydration, interaction with DNA and its condensation [11-14]. In our previous work 
[15] the influence of the polar head-group on transfection efficiency together with cell viability 
was studied in HEK-293, ARPE-19 and MSC-D1 cells. Although promising results were obtained, 
such studies were performed with lipids containing a serinol backbone, which due to its low 
biodegradability reduced significantly cell viability. Therefore in the present manuscript, we 
have modified the serinol backbone by a glycerol one in order to improve the design of the 
niosomes formulation for in vivo retinal and brain delivery purposes.  
Regarding the applications of gene therapy, the eye has favorable characteristics for 
this type of therapy, such as small size, immune-privileged position and well-defined 
compartmentalized anatomy, which minimize potential adverse reactions [16]. Additionally, 
most of the devastating inherent diseases in the eye are well described and their genetic 
background is also well known. However, at present few effective treatments are available for 
inherent retinal diseases. Therefore, research on the design of novel formulations for gene 
delivery to the retina represents a promising approach in order to translate animal research 
into clinical trials [17]. On the other hand, neurological disorders are the most difficult diseases 
to treat with clinical pharmacological approaches, mainly due to the complexity of the nervous 
system and the different brain physical barriers that drugs need to overcome after systemic 
administration [18]. Gene therapy represents a promising alternative to the traditional 
pharmacological approaches to face many devastating genetic diseases of the brain, such as 
Batten disease [19], Canavan disease [20] or Parkinson's disease [21]. In the past few years 
many gene transfer methods have been developed to treat retinal and brain diseases. 
However, all gene clinical trials are based on viral vectors that generate moderate optimism to 
drive the field forward. Therefore, we present an alternative and a safer approach to confront 
inherent retinal and brain disorders by the use of niosomes as non-viral carriers for gene 
delivery purposes.  
Consequently, in the present study, we designed niosomes vectors for retinal and 
brain delivery purposes based on three synthetic ionizable cationic lipids containing 
polysorbate 80, as a non-ionic surfactant and squalene, as a helper lipid. These cationic lipids 
had three different functional domains: 1) an hydrophobic tail formed by two saturated 
hydrocarbonated alkyl chains of fourteen atoms of carbons in length; 2) a polar head formed 
by an amino group (lipid 1), a glycine triglycine (lipid 2) and a dimethylaminoethyl group (lipid 
3) and 3) a glycerol-based building block. Niosomes prepared by the oil-in-water emulsion 
(o/w) and film hydration techniques were characterized in terms of size, PDI, zeta potential, 
morphology and physical stability. Upon the addition of the pCMS-EGFP reporter plasmid, we 
obtained nioplexes at different cationic lipid/DNA ratios (w/w). The influence of cationic 
lipid/DNA ratios on particle size, zeta potential and the ability to condense, release and protect 
DNA from enzymatic digestion was analyzed. In vitro experiments were performed and 
analyzed by flow cytometry to evaluate the most promising formulations in terms of 
transfection efficiency, viability and mean fluorescence intensity (MFI) in human embryonic 
kidney 293 cells (HEK-293), retinal pigment epithelia 19 cells (ARPE-19) and rat primary 
embryonic cerebral cortex cells (PECC). In order to move forward and according to the 
previous characterization results of the noisome formulations and nioplexes, we carried out 
some preliminary in vivo studies by confocal microscopy to evaluate transfection efficiency of 
the most promising formulation in the rat retina after intravitreal and subretinal injection and 
in the rat brain after injection in the cerebral cortex. 
 
2. Material and methods 
 
2.1. Material 
All reactions were carried out under an inert atmosphere of argon. Flash column 
chromatography was carried out on silica gel SDS 0.063e0.2 mm/70e230 mesh. 
1
H and 
13
C 
NMR spectra were recorded at 25 ºC on a Varian Mercury 400 MHz spectrometer using 
deuterated solvents. Tetramethylsilane (TMS) was used as an internal reference (0 ppm) for 
1
H 
spectra recorded in CDCl3 and the residual signal of the solvent (77.1 ppm) for 
13
C spectra. For 
CD3OD and d6-DMSO the residual signal of the solvent was used as a reference. Chemical shifts 
are reported in parts per million (ppm), coupling constants (J) in Hz and multiplicity as follows: 
s (singlet), d (doublet), t (triplet), q (quadruplet), quint (quintuplet), m (multiplet) and br 
(broad signal). Electrospray ionization mass spectra (ESI-MS) were recorded on a Micromass 
ZQ instrument with a single quadrupole detector coupled to an HPLC, and high resolution (HR) 
ESI-MS on an Agilent 1100 LC/MS-TOF instrument (Servei d’Espectrometría de Masses, 
Universitat de Barcelona). HEK-293 cells, ARPE-19 cells, Eagle's Minimal Essential medium with 
Earle's BSS and 2 mM L-glutamine (EMEM) were obtained from the American Type Culture 
Collection (ATCC). Dulbecco's Modified Eagle's medium Han's Nutrient Mixture F-12 (1:1), 
Trypsine, Hank's Balanced Salt Solution (HBSS), Neurobasal medium (NB), Fetal bovine Serum 
(FBS), B27® and Glutamax™ supplements and Penicillin-Streptomycin (Pen/Strep) antibiotics 
were purchased from Gibco® (San Diego, California, US). The plasmid pCMS-EGFP was 
purchased from Plasmid Factory (Bielefeld, Germany). The gel electrophoresis materials and 
gel red solution were acquired from Bio-Rad (Madrid, Spain). DNase I, sodium dodecyl sulfate 
(SDS), squalene, polysorbate 80, PBS and paraformaldehyde were purchased from 
SigmaeAldrich (Madrid, Spain), and dichloromethane (DCM) was purchased from Panreac 
(Barcelona, Spain). Opti-MEM® reduced medium, antibiotic/antimycotic solution and 
Lipofectmanine™ 2000 transfection reagent were acquired from Invitrogen (San Diego, 
California, US). The BD Viaprobe kit was obtained from BD Biosciences (Belgium). 
 
2.2. Synthesis of ionizable cationic amino lipids 
The synthesis of the ionizable cationic amino lipids is summarized in Supplementary 
Data Scheme S1. Synthesis of tert-butyl-N-[2-[[2-[[2-[2,3-di(tetradecoxy)propylamino]-2-oxo-
ethyl]amino]- 2-oxo-ethyl]-amino]-2-oxo-ethyl]carbamate (3). Firstly, the carboxylic acid 
activation was carried out as follows: glycine tripeptide (2.0 eq) and N-hydroxysuccinimide (2.1 
eq) were dissolved in DCM (3 mL) and the solution was stirred for a couple of minutes. Then, 
EDC (2.2 eq) was added. The reaction was stirred overnight at room temperature. The organic 
layer was washed with water (3 x 5 mL) and dried over anhydrous MgSO4. The combined 
organic layers were reduced in vacuo and the anticipated crude was used in the next step 
without further purification. Cationic lipid 1 (compound 2) (100 mg; 0.206 mmol) was added 
over the activated tripeptide. Reaction was heated at 60 ºC and stirred overnight. The solvent 
was evaporated and the resultant crude was purified by flash chromatography (DCM/MeOH 
5%). 
 
Synthesis of 2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-N-[2,3-di(tetradecoxy)propyl]-
acetamide (4, lipid 2). Boc-protected alkyl tripeptide 3 (50 mg; 0.066 mmol) was dissolved in 
DCM (1 mL) and trifluoroacetic acid was subsequently added (10%). The solution was stirred 
for one at room temperature. The solvent was removed until dryness. Finally, the anticipated 
trifluoroacetate salt was dissolved in a mixture of AcOEt:MeOH (3:2) and carbonate on 
polymer support (20 eq) was added. The mixture was stirred for 1 h at room temperature. The 
resin was filtered off and solvent was reduced until dryness obtaining the corresponding 
cationic lipid 4, which was used without further purification. 
 
Synthesis of 1-(2-dimethylaminoethyl)-3-[2,3-di(tetradecoxy) propyl]urea (5, lipid 3). 
Previously, p-nitrophenyl-chloroformate (2.5 eq) and amino diol 2 (100 mg; 0.206 mmol) were 
dissolved in a mixture of tetrahydrofurane and DCM (1:1) (6 mL). The reaction was cooled at 
0ºC and DIEA (2.5 eq) was carefully added dropwise. The solution was stirred for 4 h and 
heated at room temperature. The solvent was removed and the resultant crude was used in 
the next step without further purification. The yellow crude was dissolved in DMF (3 mL) and 
the corresponding dimethylamine derivative (1.1 eq) was added dropwise. The reaction was 
stirred overnight at room temperature. Finally, solvent was removed and the resultant crude 
was purified by flash chromatography (DCM:MeOH 5%e10%). 
 
2.3. Preparation of niosomes and nioplexes 
Niosomes based on three different synthetic cationic lipids were prepared using the 
o/w emulsification and the film-hydration techniques, as previously reported [15]. In the o/w 
emulsification technique, the cationic lipid (5 mg) was gently grounded with 23 ml of squalene 
and then emulsified in an aqueous phase containing polysorbate 80 (0.5%, w/w). The emulsion 
was obtained by sonication (Branson Sonifier 250, Danbury) for 30 s at 50W. The organic 
solvent was removed from the emulsion by evaporation under magnetic agitation for 3 h. In 
the film-hydration technique, the lipid compounds (5 mg cationic lipid and 23 ml squalene) 
were grounded in DCM, and then the solvent was evaporated under magnetic agitation for 3 h. 
Then, the lipid film was hydrated with the aqueous phase containing the non-ionic surfactant 
polysorbate 80 (0.5%, w/ w), and the emulsion was obtained by sonication for 30 s at 50 W. 
The final cationic lipid concentration was 1 mg/ml.  
The nioplexes (niosome/DNA vectors) were elaborated by mixing an appropriate 
volume of a stock solution of the pCMS-EGFP plasmid (0.5 mg/ml), which was propagated and 
purified as previously reported [15] with different volumes of the niosome suspensions for 30 
min at room temperature. The niosome/DNA ratio was referred as the ratio of cationic lipid to 
DNA (w/w). The stock solutions of cationic lipids (1 mg/ml) correspond to the following molar 
concentrations: 2.07 mM (Lipid 1, MW 484), 1.53 mM (Lipid 2, MW 654), and 1.67 mM (Lipid 3, 
MW 598). The stock solution of plasmid pCMS-EGFP (0.5 mg/ml) was estimated to be around 
0.137 mM (pCMS-EGFP, 5541 bp, average MW 3657060). 
 
2.4. Size and zeta potential of niosomes and nioplexes and Cryo- TEM analysis of niosomes  
Dynamic Light Scattering (DLS) and Laser Doppler Velocimetry (LDV) were applied to 
measure hydrodymanic diameter and zeta potential of the niosomes and nioplexes in a 
Zetasizer Nano ZS (Malvern Instrument, UK). Particle size reported as hydrodynamic diameter 
was obtained by Z-average (cumulants means). Niosomes or nioplexes were resuspended 0.1 
mM NaCl solution. All measurements were carried out in triplicate. Only data that met the 
quality criteria according to the software program were included in the study. Cryo 
Transmission Electron Microscopy (Cryo-TEM) was employed to analyze the morphology of 
niosomes, as previously described [15]. 
 
2.5. Physical stability study of niosomes 
Niosomes based on three different synthetic cationic lipids were storage for 100 days 
at 4 ºC and 25 ºC. Their physical stability was determined by monitoring the particle size and 
zeta potential during storage time. All samples were measured in triplicate. 
 
2.6. Agarose gel electrophoresis studies of nioplexes 
In order to analyze the ability of the niosomes to condensate, release and protect the 
DNA, we carried out an agarose gel electrophoresis assay with the nioplexes at different 
cationic lipid/DNA ratios (200 ng of DNA per well). The agarose gel (0.8%) was immersed in a 
Tris-acetate-EDTA buffer and exposed for 30 min to 120 V. DNA bands were stained with 
GelRed™ (Biotium, Hayward, California, USA) and images were observed with a ChemiDoc™ 
MP Imaging System. SDS 3.5% solution and DNase I enzyme (1 U DNase I per 2.5 mg DNA) 
were added to the samples to evaluate the release and protection, respectively. The integrity 
of the DNA in each sample was compared to a control of untreated DNA. 
 
2.7. Cell culture and in vitro transfection protocols 
HEK-293 and ARPE-19 cells were seeded in 24 well plates at an initial density of 15 x 
10
4
 and 10 x 10
4
 cell per well, with 300 µl of EMEM containing 10% horse serum and 300 µl of 
D-MEM/F-12 containing 10% bovine serum, respectively. Cells were incubated overnight to 
achieve 70-90% of confluence at the time of transfection. Experimental procedures for PECC 
cells were carried out conformed to the directive 2010/63/EU of the European Parliament and 
of the Council, and the RD 53/2013 Spanish regulation on the protection of animals use for 
scientific purposes and was approved by the Miguel Hernandez University Committee for 
Animal use in Laboratory. Dissociated cultures of hippocampal neurons were obtained from 
E17.5 rat embryos (Sprague Dawley) and preserved in HBSS during extraction. Then, trypsin 
was added to the medium and incubated in a bath at 37 ºC for chemical dissociation. 
Subsequently, the tissue was mechanically dissociated in NB/FBS and the cell density was 
determined using a hemocytometer. Cells were seeded on glass coverslips (Thermo Scientific) 
at approximately 100,000 cells/well cell density in a 12 well plate (Corning Incorporated) and 
maintained in a NB/FBS medium supplemented with B27, Glutamax and Pen/Strep (1:100 
dilution) in an incubator at 37 ºC and 5% CO2. At the time of transfection assay, the regular 
growth mediums were removed from ARPE-19, HEK-293 and PECC cells, and the cells were 
exposed to nioplexes resuspended in Opti- MEM® transfection medium at different cationic 
lipid/DNA ratios. The amount of plasmid for each well was 1.25 µg. Each formulation was used 
in triplicate. After 4 h of incubation at 37 ºC, the nioplexes were replaced by 300 µl of regular 
growth medium. Cells were allowed to grow for 72 h until flow cytometry analysis. Following 
the manufacturer's protocol, Lipofectamine™ 2000 was used in combination with pDNA as a 
transfection positive control. 
 
2.8. Transfection efficiency and cell viability 
Flow cytometry analysis was conducted using a FACSCalibur system flow cytometer 
(Becton Dickinson Bioscience, San Jose, USA) in order to quantify the percentage of EGFP 
positive cells. Cells were washed twice with PBS and detached from the microplate with 200 µl 
of trypsin/EDTA. Once the cells were detached, 400 µl of their respective normal growth 
medium were added and directly introduced into the flow cytometer. Transfection efficiency 
was expressed as the percentage of EGFP positive cells at 525 nm (FL1) after excluding dead 
cells. MFI data were obtained from live positive cells at 525 nm (FL1). Cell viability of the cells 
was evaluated using 5 µL of BD Via Probe reagent in each sample and positive cells were 
excluded from the EGFP expression analysis. The fluorescent signal corresponding to dead cells 
was measured at 650 nm (FL3). Control samples (non-transfected cells) were displayed on a 
forward scatter (FSC) versus side scatter (SSC) dot plot to establish a collection gate and 
exclude cells debris. Control samples containing Lipofectamine™ 2000 transfected cells 
without BD-Via Probe, and non-transfected cells with BD-Via Probe were used to compensate 
FL2 signal in FL1 and FL3 channels. For each sample 10,000 events were collected. Each 
formulation was analyzed in triplicate. 
 
2.9. In vivo studies in rats 
Adult male Sprague Dawley rats (6-7 weeks old, 200-300 g weight) were used as 
experimental animals. All experimental procedures were carried out in accordance with the 
Spanish and European Union regulations for the use of animals in research and the Association 
for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in 
ophthalmic and vision research and supervised by the Miguel Hernandez University Standing 
Committee for Animal Use in Laboratory. The surgical procedures used for the administration 
of the vectors in the retina and brain have been described elsewhere [22,23]. 
 
2.9.1. Intravitreal and subretinal injections 
Six adult male Sprague Dawley rats were used for this assay; three rats received 
injection of nioplexes by intravitreal and three by subretinal route. Injections were performed 
under an operating microscope (Zeiss OPMI® pico; Carl Zeiss Meditec GmbH, Jena, Germany) 
with the aid of a Hamilton microsyringe (Hamilton Co., Reno, NV). A bent 34-gage needle was 
used to inject into the vitreous of the left eye, closely adjacent to the ora serrata without 
touching the lens. In order to deliver the formulation into the subretinal space, the needle was 
passed through the sclerotomy 2 mm posterior to ora serrata and in a tangential direction 
toward the posterior retinal pole along the subretinal space. Successful administration was 
confirmed by the appearance of a partial retinal detachment by direct ophthalmoscopy of the 
eye fundus. The untreated right eye, served as a control. Seven days post-injection, the rats 
were sacrificed and perfused with saline solution (0.9%) followed by paraformaldehyde (4%) in 
phosphate buffer (0.1M, pH 7.2-7.4) at 4 ºC. 
 
2.9.2. Evaluation of EGFP expression in rat retinas  
All preparations were mounted as follows. Both eyes from each group were 
enucleated and immersed for 1 h in a solution of PBS with paraformaldehyde (4%). Later, the 
retinas were dissected as whole-mounts by making four radial cuts. Retinal orientation was 
maintained by making the deepest radial cut in the superior retina. The retinas were post-fixed 
for 1 h in the same fixative medium, rinsed with PBS, and mounted in poly-L-lysine coated 
microscope slides with the vitreal side facing up, covered with anti-fading mounting media 
containing glycerol (50%) and p-phenylenediamine (0.04%) in sodium carbonate buffer (0.1 M, 
pH 9.0). In order to identify retinal nuclei, the samples were stained with Hoechst 33342. 5 
mg/ml of dye was added to the samples and left for 5 min, then samples were thoroughly 
washed with PBS (0.1 M) and covered with anti-fading mounting media. EGFP expression and 
Hoechst 33342 staining were evaluated with a Leica TCS SPE spectral confocal microscope 
(Leica Microsystems GmbH, Wetzlar, Germany). Images were processed, montaged and 
composed digitally using ImageJ, (National Institutes of Health, Bethesda, MD) and Adobe® 
Photoshop® CS5.1 (Adobe Systems Inc, San Jose, CA) software. Hoechst 33342 staining was 
pseudocolored in red for better contrast. 
 
2.9.3. Brain administration 
Data were obtained from male Spraguee Dawley adult rats. Surgical analgesia was 
induced by buprenorphine (0.025 mg/kg, s.c) and anesthesia and sedation were induced by a 
cocktail of ketamine HCl (40 mg/kg, i.p) and diazepam (5 mg/kg, i.p). Subsequently, the 
anesthesia was continued and maintained with a mix of oxygen and 2% of isofluorane for the 
rest of the surgery. The effect of the anesthesia was continuously evaluated by monitoring 
heart rate, blinking and toe pinch reflexes. Rats were pre-treated with dexamethasone (1 
mg/kg, i.p) 24 h previous to the surgery and administered again 20 min before and 24 h after 
surgery. Briefly, we drilled a small craniotomy while 0.8 µl of nioplexes were incubated for 30 
min at room temperature. Then, the nioplexes were injected inside the cerebral cortex with a 
microsyringe (Hamilton company, 33-gage needle) 1 mm. Once the procedure was finished, 
the animals were housed in their own cages for 3 days. A post-surgery treatment with 
antibiotics (enroflorxacine 25 mg/kg, s.c), anti-inflammatory and analgesic drugs (meloxicam 2 
mg/kg, s.c) was administrated. 
 
2.9.4. Evaluation of EGFP expression in the rat brain 
Intracardiac perfusion with phosphate buffer solution followed by paraformaldehyde 
(4%) was performed for an initial fixation. Then, the brains were preserved in 
paraformaldehyde (4%) and cryoprotected in sucrose solution (30%) with PBS before slicing. A 
cryostat (HM 550; Microm International GmbH, Walldorf, Germany) was used to obtain slices 
of 20 mm from coronal frozen sections adjacent to the injection area. Once the slices were 
mounted for immunohistochemistry processing, sections were incubated in normal bovine 
serum (10%) (Jackson, West Grove, PA, USA) with Triton X-100 (0.5%) for blocking of non-
specific staining. Then, the samples were incubated overnight at room temperature with 
chicken anti-GFP (Invotrogen, 1:100) and rabbit anti-NeuN (Millipore, 1:300) antibodies diluted 
in PBS containing Triton- X100 (0.5%). Later, sections were washed in PBS and incubated for 1 
h with Alexa Fluor 488-conjugated donkey anti-rabbit IgG and Alexa fluor 555-conjugated 
donkey anti-chicken IgG (Invitrogen, 1:100). Hoechst 33342 was used to label the cell nuclei. 
Finally, sections were mounted for imaging and analyzed with a Leica TCS SPE fluorescence 
microscope (Leica, Microsystems GmbH, Germany). Hoechst 33342 staining was 
pseudocolored in red for better contrast. 
 
3. Results and discussion 
 
3.1. Synthesis of ionizable cationic amino lipids 
 
The search of pH-responsive drug delivery systems is one of the main strategies that 
have been used to carry out more efficient processes of drug release in acid environment. This 
mechanism normally protects therapeutic molecules at physiological pH whereas accelerates 
such release in the presence of acid pH caused by late endosomes or lysosomes in which pH 
can vary from 6.5 to 4.5, respectively. This pH dependence on mediating cellular 
internalization has been recently reported for eliciting gene silencing in vivo [24].  
In this systematic study, a tight correlation between acid dissociation constant (pKa) 
value and activity of cationic lipid based combinatorial libraries was determined by optimizing 
several variables like lipid-chain unsaturation, linker chemistry and polar head nature. 
Interestingly, an optimum pKa (6.2-6.5) was established as an ideal value in order to design 
new liposomal drug delivery systems [24]. Specifically, this optimal relationship between pKa 
and silencing activity was successfully found for amino lipid derivatives containing 
dimethylaminoethyl as a cationic pendent group. This correlation in the transfection activity 
was also observed in our recent work based on serinol amino lipid derivatives [15]. These 
findings made us to consider the possibility of introducing this potential modification in our 
glycerol-based cationic lipid 1 (Fig. 1) which efficiently promoted cellular uptake with improved 
values compared to commercially available cationic lipids. As comparison purposes, we also 
selected triglycine tripeptide in its free amine form in order to investigate further additional 
effects that could govern transfection efficiency processes when increased the polarpendent 
group electronic nature.  
The synthetic strategy for obtaining our small library of glycerolbased cationic lipids is 
displayed in scheme S1 (see supplementary part for additional details). The synthesis of the 
cationic lipid 1 (compound 2) was previously reported by our research group [7]. In order to 
further functionalize the free amine group of the amino lipid 2 with a triglycine peptide, 
carboxylic acid activation with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 
NHydroxysuccinimide (NHS) was carried out by using standard activation protocols. Thus, the 
anticipated Boc-protectedtripeptide- amino lipid 3 was obtained with moderate yields after 
purifying by flash chromatography (70%). Final Boc-deprotection was efficiently done with acid 
treatment (10% trifluoroacetic acid) in DCM, which afforded the corresponding free amine in 
its trifluoroacetate form. Treatment with carbonate polymer support liberated the amine and 
the expected triglycine-amino lipid derivative 4 (cationic lipid 2) was obtained after resin 
filtration (87%). Finally, the introduction of the dimethylaminoethyl pendent group was 
accomplished by activating the amine group from amino lipid 2 with p-nitrophenyl-
chloroformate according to well-stablished protocols [15]. Final nucleophilic reaction 
introduced the corresponding dimethylaminoethyl residue and generated the expected urea 
derivative 5 (cationic lipid 3) with moderate yield (65%). Since these modifications have not 
been studied yet, we tentatively chose these three pendant groups in order to be incorporated 
to the glycerol building block (lipid 1, lipid 2 and lipid 3). 
 
 
 
Fig. 1. Chemical structures of cationic lipids. Lipid 1: 2, 3-bis (tetradecyloxy) propan-1- amine. 
Lipid 2: 2-amino-N-(((((2, 3-bis (tetradecyloxy) propyl) carbamoyl) methyl) carbamoyl) methyl) 
acetamide. Lipid 3: 1-(2-dimethylaminoethyl)-3-[2,3-di (tetradecoxy) propyl] urea. 
 
 
3.2. Particle size, PDI, zeta potential and morphology of niosomes 
Niosomes based on the three cationic lipids prepared by o/w emulsion and film-hydration 
techniques were characterized in terms of Z-average (cumulants) size, PDI, zeta potential and 
morphology (Fig. 2). We observed that zeta potential values were similar in both techniques 
for the niosome formulations based on lipid 1 (+47 mV) and lipid 3 (+43 and + 36 mV for o/w 
emulsion and film hydration, respectively) (Fig. 2A lines). On the other hand, for the niosomes 
prepared with the lipid 2, there was a considerable difference of 20 mV in the zeta potential 
between the two techniques (+37 and + 59 mV for o/w emulsion and film-hydration, 
respectively) (Fig. 2A, lines). In any case, all niosome formulations exhibited positive zeta 
values over 30 mV, which enhanced the formation of stable suspensions due to the repulsion 
among the positively charged particles [25]. Additionally, these positive charges also allowed 
an easy interaction with the negatively charged cell surfaces to increase cell uptake [26].  
 
 
Fig. 2. Physicochemical characterization of niosomes based on lipid 1, 2 and 3. A) Z-average 
(cumulants) size (white and gray bars, which correspond to niosomes prepared by 
filmhydration and o/w emulsion techniques, respectively) and zeta potential values (dotted 
and continuous lines which correspond to niosomes prepared by film-hydration and o/w 
emulsion techniques, respectively). B) PDI values. Each value represents the mean ± standard 
deviation of three measurements. C) Cryo-TEM images of niosomes prepared by the o/ w 
emulsion technique. C1) Niosomes based on lipid 1, C2) niosomes based on lipid 2 and C3) 
niosomes based on lipid 3. Scale bar for figures C1 and C3 = 100 nm and for figure C2 = 200 
nm. 
 
Regarding particle size values (Fig. 2A, bars), we did not find remarkable differences 
between the niosomes when they were elaborated by the o/w emulsion or film-hydration 
technique. In all cases, the particle size was around 200 nm. As a homogeneity parameter of 
the suspensions, we determined the polydispersity index (PDI) (Fig. 2B). Lower PDI values 
(0.19, 0.17 and 0.21 for lipid 1, 2 and 3, respectively) were found in niosomes prepared by o/w 
emulsion when they were compared to niosomes prepared by film hydration technique (0.35, 
0.99 and 0.51 for lipid 1, 2 and 3, respectively), which showed that the size distribution of 
niosomes prepared by the o/w emulsion was narrower than the size distribution obtained by 
film-hydration technique. Since it has been previously reported that narrow distribution of the 
PDI values enhances the uptake and posterior internalization process of the nanoparticles 
[27,28], we decided to discard the niosomes prepared by the film-hydration technique for the 
following experiments.  
The morphology of niosomes based on the three cationic lipids and elaborated by the 
o/w emulsion technique was analyzed by Cryo-TEM (Fig. 2C1, C2 and C3). We observed that all 
niosomes adopted a spherical and homogeneous morphology. Additionally, the size observed 
in all niosome formulations by Cryo-TEM (around 100 nm) appeared to be smaller than the 
sizes reported by dynamic light scattering (around 200 nm, Fig. 2A, bars). Differences in the 
reported size between DLS and Cryo-TEM techniques could be explained by the treatment of 
the sample when are processed by both analyses [15].  
Based on the data obtained from the physicochemical properties of the niosome 
formulations, such as size (around 200 nm, Fig. 2A bars), zeta potential (over +37 mV, Fig. 2A 
lines), morphology (spherical and homogeneous, Fig. 2C 1,2,3) and the significant differences 
in the PDI values (Fig. 2B), we determined that the niosomes prepared by o/w emulsion 
technique were the most suitable candidates for the following assays. 
 
 
3.3. Physical stability of niosomes 
Physical stability of niosomes based on the three cationic lipids prepared by o/w 
emulsion technique is represented on Fig. 3, as a measure of particle size and zeta potential 
value over the time at 4 and 25 ºC. Regarding zeta potential data, all the niosomes stored at 4 
ºC did not show relevant changes (Fig. 3A, B and C lines), especially niosomes based on lipid 2 
(þ40 mV, Fig. 3B continued line). On the other hand, when formulations were stored at 25 ºC, 
remarkable decreases on the zeta potential values were found on niosomes elaborated with 
lipid 1 and 3 from +40 to -20 mV (Fig. 3A dot line) and from +43 to +2 mV (Fig. 3C dot line), 
respectively. This decrease at temperatures around 25 ºC can be explained by the re-
orientation of crystalline structure of the lipids at high temperatures that is followed by a 
change on the particle surface, which reduces the zeta potential [29]. The size of the niosomes, 
as shown in Fig. 3 (gray bars), remained stable for all conditions at 4 ºC. However at 25 ºC 
storage temperature, niosomes based on lipid 3 increased their size (250 nm) after 100 days 
(Fig. 3C, white bars). This increase of the particle size can be caused by gradual diminution of 
the positive charges of the particles that decreases electrostatic repulsion and generates 
aggregates [25]. 
 In general, more stable formulations over the time in terms of size and charge were 
achieved at 4 ºC, where the positive superficial charge of niosomes last longer time. At this 
temperature condition, the high charges avoid the formation of niosome aggregates due to 
electrostatic repulsion forces. These findings about the zeta potential and size of the niosomes 
suggest that storage temperature plays an important role in the stability of our niosomes. 
Moreover, these data also highlighted the participation of the polar head-groups in the 
physical stability of niosomes, where the implication is more evident in the zeta potential 
values at 25 ºC.  Similar results were observed in previous reported data [15]. 
 
 
 
 
 
 
 
Fig. 3. Physical stability of niosomes based on lipid 1 (A), lipid 2 (B) and lipid 3 (C) following 
storage at 4 ºC and 25 ºC for 100 days. Gray and white bars correspond to Z-average 
(cumulants) size obtained at 4 ºC and 25 ºC, respectively, while continuous and dotted lines 
correspond to zeta values obtained at 4 ºC and 25 ºC. Each value represents the mean ± 
standard deviation (SD) from three independent experiments. 
 
 
 
 
 
 
Fig. 4. The influence of the cationic lipid/DNA ratio (w/w) on the particle Z-average (cumulants) 
size (bars) and zeta potential (lines) of nioplexes based on: (A) lipid 1, (B) lipid 2 and (C) lipid 3. 
Each value represents the mean ± standard deviation of three measurements. 
 
3.4. Characterization of nioplexes in terms of zeta potential and size 
Nioplexes formed by the addition of DNA to the niosomes at different cationic 
lipid/DNA ratios (w/w) were characterized in terms of charge and size (Fig. 4). The results 
showed a significant decline in zeta potential values (Fig. 4, lines) in the three niosomes 
formulations when DNA was added at 1/1 cationic lipid/DNA mass ratio (w/w). These changes 
were observed especially for niosomes based on lipid 2; zeta potential value decreased from 
+31 mV to -57 mV (Fig. 4B, line). However, we observed a constant increment of the zeta 
potential values in all nioplexes formulations with the increment of cationic lipid/DNA 
proportion. The maximum positive zeta potential values were observed at 30/1 cationic 
lipid/DNA ratio (w/w) (+35 mV, +31 mV and +27 mV for nioplexes based on lipids 1, 2 and 3, 
respectively). Our data showed a clear correlation between the cationic lipid/DNA ratios and 
the superficial charge of the nioplexes, as previously reported [15]. Hence, we can establish an 
appropriate ratio between cationic lipid and DNA (For lipid 1 and 3 at 6/1 ratio and for lipid 2 
at 10/1 ratio (w/w)) to reach positive values, so that nioplexes can interact easily with 
negatively charged cell membranes.  
Concerning about the size of all nioplexes formed with the three niosome formulations 
(Fig. 4, bars), they did not show relevant differences at mass ratios from 1/1 to 30/1, except 
lipid 2 at ratio 6/1 (230 nm). Size of the nioplexes can depend on a fragile balance between the 
ability of cationic lipids to condense the DNA, which can reduce the particle size, and the space 
demanded by the lipid [7]. Thus, we can explain the slight variation of the size from the lowest 
to the highest ratio. In general, most of the nioplexes showed a final size below 200 nm, which 
is a suitable size to be internalized by the cells [30]. 
 
3.5. Agarose gel electrophoresis studies of nioplexes 
In order to analyze the electrostatic interactions between the niosomes based on the 
cationic lipids 1, 2 and 3 and the DNA, we performed an agarose gel electrophoresis assay. 
Moreover, to study the DNA release, we added SDS to the formulations to simulate an ideal 
gene delivery condition, where all the cargo is released in the media. We also studied the 
capacity of niosomes to protect DNA against enzymatic digestion. Based on zeta potential and 
size data, we selected 6/1, 10/1, 20/1 and 30/1 cationic lipid/DNA ratios (w/w) to perform the 
agarose gel electrophoresis studies since at cationic lipid/DNA ratios below 6/1, the zeta 
potential values were negative. The agarose gel electrophoresis assays are shown in Fig. 5, 
where SC bands show the most bioactive DNA form and OC bands represent structural change 
of DNA of a less active form [31]. Nioplexes were analyzed in terms of condensation, release 
and protection of DNA.  
First, regarding nioplexes based on cationic lipid 1 (Fig. 5A), the results showed 
deficient condensation of DNA (lanes 4, 7, 10 and 13), as SC bands were shown in the agarose 
gel. Moreover, DNAwas easily released from the niosomes at mass ratios 6/1 and 10/1 (lanes 5 
and 8) upon the addition of the tensoactive agent SDS, as a possible consequence of poor 
condensation. We also found that at mass ratios 20/1 and 30/1 there was a weak release of 
DNA, as white lines were observed at the top of the wells (lanes 11 and 14). This effect was 
probably due to high zeta potential values (around + 32 mV) obtained at those ratios. In 
addition, protection of DNA can be observed at all mass ratios. The SC bands in lanes 6, 9, 12 
and 15 showed that nioplexes protected the DNA from enzymatic digestion.  
Second, regarding nioplexes based on the cationic lipid 2 (Fig. 5B), all ratios were able 
to condensate the DNA (lanes 4, 7, 10 and 13). The presence of several amino groups in this 
lipid may be the cause of this level of condensation. On the other hand, the release of DNA at 
all mass ratios was difficult (lanes 5, 8, 11 and 14), even at lower ratios. Concerning about DNA 
protection from DNase, we observed reasonable protection at all ratios. Intense OC bands can 
be observed especially at ratios 6/1, 10/1 and 20/1, which correspond to lanes 6, 9 and 12, as 
consequence of conformational change of DNA to open circular form due to DNase 
intervention.  
Finally, nioplexes based on the cationic lipid 3 (Fig. 5C) indicated that high DNA 
condensation was only observed with nioplexes at 30/1 cationic lipid/DNA ratio (w/w) (lane 
13), probably due to the high zeta potential values obtained at this ratio (þ27 mV). Moreover, 
niosomes based on cationic lipid 3 were able to release the DNA especially at low ratios (6/1, 
lane 5 and 10/1, lane 8). Concerning about protection against enzymatic digestion, nioplexes 
showed that DNA was properly protected in all cases (lanes 6, 9, 12 and 15).  
To summarize, data obtained from agarose gel electrophoresis studies, suggested that 
nioplexes based on the three cationic lipids, at low ratios (6/1) were less efficient to 
condensate, release and protect the DNA against enzymatic digestion. Thus, these outcomes 
indicated that nioplexes based on lipid 1, 2 and 3 at ratios (w/w) 10/ 1, 20/1 and 30/1 were 
more suitable to succeed in the transfection experiments. 
 
 
Fig. 5. Binding, protection, and SDS-induced release of DNA from nioplexes at different 
lipid/DNA (w/w) ratios visualized by agarose electrophoresis. OC: open circular form, SC: 
supercoiled form. Lanes 1-3 correspond to free DNA; lanes 4-6, cationic lipid/DNA ratio 6/1; 
lanes 7-9, cationic lipid/DNA ratio 10/1; lanes 10-12, cationic lipid/DNA ratio 20/1; lanes 13-15, 
cationic lipid/DNA ratio 30/1. Nioplexes were treated with SDS (lanes 2,5,8,11 and 14) and 
DNase I + SDS (lanes 3,6,9,12 and 15). A) Nioplexes based on lipid 1, B) nioplexes based on lipid 
2 and C) nioplexes based on lipid 3. 
 
3.6. In vitro transfection experiments in HEK-293, ARPE-19 and PECC cells 
We carried out further in vitro assays to analyze transfection efficiencies and toxicity of 
nioplexes in the following cells: HEK-293 cells, as general cell model, ARPE-19 cells, as retinal 
cell model for possible in vivo applications in retina, and PECC cells, as neurons and glial model 
cells for the potential use of nioplexes in the brain (Fig. 6A).  
The data obtained from the nioplexes based on the cationic lipid 1 showed that the 
highest percentage of transfection efficiencies were obtained in HEK-293 cells (around 21%) 
(Fig. 6A white bars) at mass ratios 20/1 and 30/1. Additionally, suitable transfection results 
were also observed for ARPE-19 cells, where the highest transfection values were around 18% 
at 20/1 mass ratio (Fig. 6A gray bars). It must be highlighted that previous work carried out 
with serinol-based cationic lipids modified with the same lipid tail showed null transfection 
efficiency in cell culture [15]. These findings suggest that small structural changes in the lipid 
(serinol by glycerol building block) are enough to influence dramatically on transfections 
efficiencies. On the other hand, transfections in PECC cells were around 3% for all mass ratios, 
which was the lowest percent observed within the three types of cells (Fig. 6A black bars). For 
nioplexes based on lipid 2, high percentage of transfected cells were observed again (13%) in 
HEK-293 cells at ratio 20/1 (w/w) (Fig. 6A white bars). However, low transfection efficiencies 
were registered in ARPE-19 and PECC cells at all cationic lipid/DNA mass ratios (Fig. 6A gray 
and black bars, respectively). Similar results also were observed in previous data reported [15] 
where the cationic lipid formed by longer polyamine chains and more amino nitrogen atoms 
did not precisely enhanced cell transfection in HEK-293 and ARPE-19 cells. These outcomes are 
probably due to self-folded conformation that disfavor effective interaction with DNA. It also 
must be emphasized that presence of more than one carbonyl group in the polar head-group 
seems to be also an impediment for efficient cell transfections [32,33]. Regarding nioplexes 
based on lipid 3, transfections around 20% were obtained in HEK-293 cells at 30/1 mass ratio 
and lower transfections at 10/1 mass ratio (Fig. 6A white bars). Percentage of transfected cell 
levels in ARPE-19 cells also showed promising results (19%) at 30/1 mass ratio; similar to the 
data observed in HEK-293 cells. However, decrease in transfection efficiencies was observed at 
lower mass ratios (Fig. 6A gray bars). Furthermore, interesting data were obtained in PECC 
cells, especially at 30/1 mass ratio, where transfection was around 5% (Fig. 6A black bars). For 
further details regarding confocal microscopy images from transfected cerebral cortical cells, 
see Supplementary Data, Fig. S1. Cultured neurons are among the most difficult cells to be 
transfected due to their sensitivity to microenvironmental changes and they tend to die soon 
after transfection. Typical transfection efficiencies in this kind of cells are around 5% [34]. 
Interestingly, relevant transfection data in HEK- 293, ARPE-19 and MSC-D1 cells were also 
observed with a similar cationic lipid that has the same molecular formula, but different 
structural conformation [15]. In addition, this structural relationship between lipids and 
transfection has been previously reported by different authors [32,33,35], which have 
described that slight lipid structure modifications can provoke cell transfection variations.  
Cell toxicity is another important issue that has to be addressed for the development 
of any novel drug delivery system including any desired cationic lipid for its use as non-viral 
vector. Therefore, we studied the cell viability with our formulations (Fig. 6B). The results 
indicated that only HEK-293 cells showed high viabilities with nioplexes prepared with lipid 1 
(84%, 76% and 70% at 10/1, 20/ 1 and 30/1 mass ratios, respectively). On the other hand, the 
most toxic effect was observed with the lipid 2 (31% of viability) at 30/1 mass ratio (Fig. 6B 
white bars). Better toleration in ARPE-19 and PECC cells (Fig. 6B gray and black bars, 
respectively)was found with nioplexes at all studied ratios (100% of viability) (Fig. 6B gray and 
black bars). It must be stressed that toxicity effect is, generally, a cell dependent process 
where every cell type shows different toleration levels [36]. Furthermore, the structure design 
of the cationic lipids also influences on the cell viability, such as small changes on the polar 
head-groups that can induce different levels of cytotoxicity [15,37]. It is worth mentioning that 
cationic lipids containing one or three hydrocarbonated alkyl chains tend to be more toxic and 
show poor transfection efficiencies [11].  
In order to describe more precisely the transfection efficiencies of our formulations, 
we analyzed the MFI of the EGFP expressed in the transfected cells. Results obtained from the 
nioplexes based on cationic lipid 1 showed that low MFI were observed in HEK-293 cells 
(around 30, Fig. 6C white bars) at all tested mass ratios. On the other hand, ARPE-19 and PECC 
cells showed higher MFI (over 40 and 80, respectively); high MFI in PECC cells were obtained at 
the three studied mass ratios (10/1, 20/1 and 30/1) (Fig. 6C black bars). Based on the data 
from nioplexes prepared with the cationic lipid 2, MFI in HEK-293 cells were around 89 at the 
different analyzed mass ratios (10/1, 20/1 and 30/1, Fig. 6C white bars). Additionally, 
expression of EGFP was similar in PECC cells at all analyzed mass ratio (10/1, 20/1 and 30/1, 
Fig. 6C black bars). MFI results from nioplexes prepared with lipid 3 revealed that HEK-293 cells 
showed low EGFP expression (MFI around 60) when compared to ARPE-19 and PECC cells. 
Furthermore, ARPE-19 cells showed the highest MFI (149) at 30/1 mass ratio (Fig. 6C gray 
bars). The MFI obtained from PECC cells was around 80, which is similar to those observed 
with the other two cationic lipids (Fig. 6C black bars). Essentially, these results indicated that 
nioplexes based on cationic lipid 3 stimulated higher EGFP expression in ARPE-19 transfected 
cells and suitable expression of EGFP in PECC and HEK-293 transfected cells at 30/1 mass ratio. 
Likewise, differences in membrane composition among cell lines can also influence cellular 
uptake and posterior intracellular trafficking processes of vectors [38]. For further MFI 
information, see histograms in Supplementary Data Fig. S2.  
 
Fig. 6. In vitro transfection experiments of nioplexes based on cationic lipid 1, 2 and 3in HEK-
293, ARPE-19 and PECC cells. A) Transfection efficiency at different cationic lipid/DNA ratios 
(w/w). B) Cell viability at different cationic lipid/DNA ratios (w/w). C) MFI of transfected cells 
with nioplexes based on cationic lipid 1, 2 and 3 in HEK-293, ARPE-19 and PECC cells at 
different cationic lipid/DNA ratios (w/w). 
Taking into account these data (Fig. 6), nioplexes based on cationic lipid 1 and 3 
showed better percentages of transfection in ARPE-19 and PECC cells. These results also 
indicate that polar headgroups of the cationic lipids play a fundamental role in transfection 
efficiencies. In addition, cell toxicity assay showed a cell dependent toxicity effect rather than a 
polar head-group effect, where major toxicity effect was observed in HEK-293 cells. For MFI 
assay, the most relevant data were obtained from cationic lipid 3, which in general expressed 
high levels of EGFP in cells. Thus, we decided to use niosomes based on lipid 3 as the most 
appropriate system for further in vivo experiments.  
Differences observed among the three cationic lipids on transfection efficiency could 
be explained, in part, by slight changes on their particle size and superficial charge that affect 
to their capacity to condense, protect and release the DNA against enzymatic digestion. 
Additionally, other physicochemical parameters related with the chemical structure of the 
polar-head group such as the balance between the cross-sectional area of the polar-head 
group (small end) and the hydrophobic domain (large end), or the pKa value should also be 
considered. The greater the imbalance between both the polar-head group and the 
hydrophobic domain, the more unstable the resulting lipid assembly and therefore, the greater 
the probability to undergo fusion with anionic vesicles [37]. Consequently, this hypothesis 
could explain the low percentages of transfected cells observed in nioplexes prepared with 
lipid 2. Regarding the pKa value, it has been suggested an optimal value slightly inferior to 7 in 
order to maintain a neutral surface charge density at pH 7.4 [39]. Previous results by our group 
have shown that dimethylaminoethyl pendent group provides pKa values that could fall in the 
optimal range for transfection (from 6.2 to 6.7) [15]. Consequently, cationic lipid 3 positive 
charge density should increase in the acidic environment of the endosome leading to a 
membrane-destabilizing process by forming ion pairs between the lipid 3 and phospholipids in 
the endosomal membrane. This process might promote a lamellar to hexagonal transition in 
the lipid 3 which might disrupt the membrane and destabilize bilayers. Additionally, the 
presence of squalene in our formulation would facilitate this kind of transition [7]. The 
combination of these two effects would make this transfection process more efficient. 
 
3.7. In vivo studies 
We carried out in vivo studies to evaluate EGFP expression in the rat retina after both 
subretinal (Fig. 7) and intravitreal (Fig. 8) injections. Both administration routes are clinically 
viable options to deliver genetic material to the retina [40]. While classically, the effect of 
subretinal injection is localized around the injection site, intravitreal injections can carry the 
delivered material to a larger retinal surface [41]. In our results, subretinal injection of 
nioplexes based on cationic lipid 3 at 30/1 mass ratio resulted in substantial protein expression 
mainly observed in photoreceptors and in some nuclei in the outer nuclear layer (Fig. 7). 
Transfection at this level could be of great interest, since most of the inherited retinal diseases 
such as Stargat Disease, Retinitis Pigmentosa, Age-related Macular Degeneration or Leber 
Congenital Amaurosis are classically associated to mutations in genes expressed in 
photoreceptors and outer nuclear layers of the retina [17]. Therefore, subretinal 
administration of nioplexes based on cationic lipid 3 could be appropriate to treat 
aforementioned retinal inherited diseases. However, subretinal administration is frequently 
associated with high risk of retinal detachment or severe lesions in the retina, which often 
dissuade its clinical application. In any case, some promising results have been obtained in 
clinical trials after subretinal injection to treat many inherited retinal diseases such as Leber 
Congenital Amaurosis Type 2 [42].  
By contrast, intravitreal injection is a safer technique in ophthalmology and is more 
widely used in the clinical practice. We found a good and uniformly distributed EGFP 
expression mainly in the ganglion cell layer and inner layers of the retina 3 days after 
intravitreal injection of nioplexes based on cationic lipid 3 at 30/1 mass ratio (Fig. 8), which 
suggests that nioplexes did not aggregate with the negatively charged components of the 
vitreous humor such as glycosamineglycanes and diffused through the inner layer of the retina, 
enhanced probably, by the ability of the PEG chains of the polysorbate 80 structure to prevent 
aggregations due to interaction with fibrilar structures in the vitreous [43,44]. Transfection at 
the inner layers of the retina could be of great interest to treat some genetic pathologies of 
the retina such us glaucoma [45] a progressive optic neuropathy that affect to retinal ganglion 
cells. Interestingly, we detected some protein expression in the retinal pigmented epithelium 
(Fig. 8E), which clearly represents a great challenge for retinal gene therapy in order to avoid 
subretinal injection to target the outer segments of the photoreceptors and the pigmented 
epithelium cells without causing harm to the sensitive neural tissue [2].  
 
 
 
Fig. 7. EGFP gene expression in retina 3 days after subretinal injection of nioplexes based on 
lipid 3 at mass ratio 30/1 cationic lipid/DNA. A), B) Retinal sections showing EGFP expression 
mainly in photoreceptors and in some nuclei in the outer nuclear layer (ONL). C) Detail of three 
EGFP
+
 cell nuclei located in the ONL. Cell nuclei were counterstained with Hoechst 33342 (red 
color) in B and C. Scale bars A, B = 40 mm; C = 25 mm. (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this article.) 
 
Additionally, we decided to evaluate the capacity of nioplexes based on lipid 3 at 30/1 
ratio to transfect the rat cerebral cortex (Fig. 9). We identified by immunochemistry analysis 
NeuNþ (red channel), NeuN
-
 cells and GFP
+
 (green channel). The NeuN
+
 corresponded to 
neurons, NeuN
-
 to non-neuronal cells, such as glial and endothelia population cells and GFP
+
 
corresponded to cells expressing EGFP. Based on the analysis, we were able to identify 
neurons and non-neuronal cells that expressed EGFP in the area next to the injection site. 
Thus, on the one hand, Fig. 9A shows NeuN
+
 cells that corresponded to neurons expressing 
high levels of GFP in the cells bodies and in their dendritic trees (white arrows). On the other 
hand, Fig. 9B shows NeuN
-
 cells with glial morphology that expressed high levels of GFP 
throughout the dendritic processes (yellow arrows). Briefly, it seems that there is a cell 
dependent effect for the nioplexes internalization and transfection process. Favorably, 
nioplexe injections did not affect the behavior of the animals and no loss of weight was 
detected during the 3 days of the experimental period. Even though delivering genetic 
material to the nervous system cells by non-viral vectors remains as a challenge, our nioplexes 
were able to transfect glial cells and identified neurons in the primary visual cortex in vivo. In 
this preliminary study, we determined that our nioplexes were able to transfect more glial cells 
than neurons. These results suggest that cell division of glial cells and the CMV promoter of 
pCMS-EGFP plasmid could be involved in the transfection process [46]. Therefore, the use of 
our nioplexes combined with plasmids holding different promoters might allow targeting 
different cell populations of the nervous system and enhance cell transfection in order to treat 
different genetic population deficits. Overall, our results open a safe alternative to the 
treatment of neurodegenerative diseases, such as Parkinson's disease. Despite the current 
advances to treat these types of diseases, neurodegenerative diseases still do not have 
effective pharmacotherapy treatments. Therefore, further research is required before these 
findings can reach the clinic. 
 
 
Fig. 8. EGFP gene expression in retina 3 days after intravitreal injection of nioplexes based on 
lipid 3 at mass ratio 30/1 cationic lipid/DNA. A) Wholemount preparation showing EGFPþ cell 
bodies located in the ganglion cell layer (GCL). B), C), D) and E) Retinal cross sections. EGFP 
expression was detected throughout the whole retina although mainly in inner layers. Cell 
nuclei were counterstained with Hoechst 33342 (red color). Scale bar ¼ 40 mm. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.) 
 
4. Conclusion 
In the present study, we designed niosomes prepared from squalene, as helper lipid, 
polysorbate 80, as non-ionic surfactant and three synthetized cationic lipids, which differed 
only in the polar head-group, to evaluate their transfection efficiency in retina and brain. Our 
results showed that the chemical composition of the cationic lipid head-groups clearly affects 
the physicochemical parameters of the niosomes and modifies the levels of transfection 
efficiencies of the nioplexes. We observed that niosomes based on cationic lipids with a 
dimethyl amino (lipid 3) and amino (lipid 1) head-groups showed remarkable percentages of 
transfection capacity when they were compared to their counterpart triglycine head-group 
(lipid 2). Regarding MFI, nioplexes based on the cationic lipid 3 showed higher protein 
expression in the transfected cells when they were compared to lipid 1. Moreover, in vitro 
results at different cationic lipid/DNA ratios (w/w) suggested that not only structural changes 
in the polar head-groups of these cationic lipids were involved in the success of these vectors, 
but also cationic lipid/ DNA ratios were deeply involved in the interaction with the cells and 
their transfection efficiencies. In vivo results showed that after subretinal, intravitreal and 
brain injections, nioplexes transfected successfully the cells in rat retina and brain. Although 
this preliminary study highlights the flattering properties of nioplexes based on lipid 3 to 
deliver genetic material to the retina and brain, additional work, such as the long term 
evaluation of the transgene expression should also be investigated in order to translate 
preclinical results in animals to clinical trials. 
 
 
 
Fig. 9. In vivo gene expression of EGFP 3 days after the administration of nioplexes based on 
lipid 3 at 30/1 mass ratio cationic lipid/DNA. A and B panels show triple labeling; nuclei are 
shown in blue (Hoechst), neurons in red (NeuN
+
), and EGFP expressed in cells (GFP
+
) in green. 
A) Several of the identified neurons (red) that express EGFP (green) in the membrane at their 
cell bodies and dendritic trees are indicated by white arrows. B) Several of the non-neuron 
cells (NeuN
-
) with glia morphology that express EGFP (green) through their processes are 
indicated by yellow arrows. Scale bar = 40 mm. (For interpretation of the references to color in 
this figure legend, the reader is referred to the web version of this article.) 
 
 
Acknowledgments 
This project was partially supported by the University of the Basque Country UPV/EHU (UFI 
11/32), the National Council of Science and Technology (CONACYT), Mexico, Reg. # 217101, 
the Spanish Ministry of Education (Grant CTQ2010-20541, CTQ2010- 14897), the Basque 
Government (Department of Education, University and Research, predoctoral BFI-2011-2226 
grant) and by Spanish grants MAT2012-39290-C02-01 and IPT-2012-0574- 300000. Technical 
and human support provided by SGIker (UPV/ EHU) is gratefully acknowledged. Authors also 
wish to thank the intellectual and technical assistance from the ICTS “NANBIOSIS”, more 
specifically by the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials & 
Nanomedicine (CIBER-BBN) at the University of Basque Country (UPV/EHU). 
 
REFERENCES 
 
 [1] H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, D.G. Anderson, Nonviral vectors 
for gene-based therapy, Nat. Rev. Genet. 15 (2014) 541-555. 
[2] P. Charbel Issa, R.E. MacLaren, Non-viral retinal gene therapy: a review, Clin. Exp. 
Ophthalmol. 40 (2012) 39-47. 
[3] M. Agirre, J. Zarate, E. Ojeda, G. Puras, L.A. Rojas, R. Alemany, et al., Delivery of an 
adenovirus vector plasmid by ultrapure oligochitosan based polyplexes, Int. J. Pharm. 479 
(2015) 312-319. 
[4] M.A. Zarbin, C. Montemagno, J.F. Leary, R. Ritch, Nanomedicine for the treatment of retinal 
and optic nerve diseases, Curr. Opin. Pharmacol. 13 (2013) 134-148. 
[5] P. Arukuusk, L. Parnaste, M. Hallbrink, U. Langel, PepFects and NickFects for the 
intracellular delivery of nucleic acids, Methods Mol. Biol. 1324 (2015) 303-315. 
[6] R. Rajera, K. Nagpal, S.K. Singh, D.N. Mishra, Niosomes: a controlled and novel drug delivery 
system, Biol. Pharm. Bull. 34 (2011) 945-953. 
[7] G. Puras, M. Mashal, J. Zarate, M. Agirre, E. Ojeda, S. Grijalvo, et al., A novel cationic 
niosome formulation for gene delivery to the retina, J. Control Release 174 (2014) 27e36. 
[8] P. Couvreur, “Squalenoylation”: a new approach to the design of anticancer and antiviral 
nanomedicines, Bull. Acad. Natl. Med. 193 (2009) 663-673 discussion 673-4. 
[9] H. Chung, T.W. Kim, M. Kwon, I.C. Kwon, S.Y. Jeong, Oil components modulate physical 
characteristics and function of the natural oil emulsions as drug or gene delivery system, J. 
Control. Release 71 (2001) 339-350. 
[10] F. Liu, J. Yang, L. Huang, D. Liu, New cationic lipid formulations for gene transfer, Pharm. 
Res. 13 (1996) 1856-1860. 
[11] G. Byk, C. Dubertret, V. Escriou, M. Frederic, G. Jaslin, R. Rangara, et al., Synthesis, activity, 
and structureeactivity relationship studies of novel cationic lipids for DNA transfer, J. Med. 
Chem. 41 (1998) 229-235. 
[12] Y.V. Mahidhar, M. Rajesh, A. Chaudhuri, Spacer-arm modulated gene delivery efficacy of 
novel cationic glycolipids: design, synthesis, and in vitro transfection biology, J. Med. Chem. 47 
(2004) 3938-3948. 
[13] P.P. Karmali, A. Chaudhuri, Cationic liposomes as non-viral carriers of gene medicines: 
resolved issues, open questions, and future promises, Med. Res. Rev. 27 (2007) 696-722. 
[14] D. Zhi, S. Zhang, B. Wang, Y. Zhao, B. Yang, S. Yu, Transfection efficiency of cationic lipids 
with different hydrophobic domains in gene delivery, Bioconjug. Chem. 21 (2010) 563-577. 
[15] E. Ojeda, G. Puras, M. Agirre, J. Zarate, S. Grijalvo, R. Pons, et al., Niosomes based on 
synthetic cationic lipids for gene delivery: the influence of polar head-groups on the 
transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells, Org. Biomol. Chem. 13 (2015) 
1068-1081. 
[16] C. Bloquel, J.L. Bourges, E. Touchard, M. Berdugo, D. BenEzra, F. Behar-Cohen, Non-viral 
ocular gene therapy: potential ocular therapeutic avenues, Adv. Drug Deliv. Rev. 58 (2006) 
1224-1242. 
[17] D.M. Lipinski, M. Thake, R.E. MacLaren, Clinical applications of retinal gene therapy, Prog. 
Retin. Eye Res. 32 (2013) 22e47. 
[18] S. Nagabhushan Kalburgi, N.N. Khan, S.J. Gray, Recent gene therapy advancements for 
neurological diseases, Discov. Med. 15 (2013) 111-119. 
[19] S. Worgall, D. Sondhi, N.R. Hackett, B. Kosofsky, M.V. Kekatpure, N. Neyzi, et al., 
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 
adeno-associated virus expressing CLN2 cDNA, Hum. Gene Ther. 19 (2008) 463-474. 
[20] P. Leone, D. Shera, S.W. McPhee, J.S. Francis, E.H. Kolodny, L.T. Bilaniuk, et al., Long-term 
follow-up after gene therapy for canavan disease, Sci. Transl. Med. 4 (2012), 165-163. 
[21] S. Muramatsu, The current status of gene therapy for Parkinson's disease, Ann. Neurosci. 
17 (2010) 92-95. 
[22] C. Soto-Sanchez, G. Martinez-Navarrete, L. Humphreys, G. Puras, J. Zarate, J.L. Pedraz, et 
al., Enduring high-efficiency in vivo transfection of neurons with non-viral magnetoparticles in 
the rat visual cortex for optogenetic applications, Nanomedicine 11 (2015) 835-843. 
[23] G. Puras, J. Zarate, M. Aceves, A. Murua, A.R. Diaz, M. Aviles-Triguero, et al., Low 
molecular weight oligochitosans for non-viral retinal gene therapy, Eur. J. Pharm. Biopharm. 83 
(2) (2012) 131-140. 
[24] M. Jayaraman, S.M. Ansell, B.L. Mui, Y.K. Tam, J. Chen, X. Du, et al., Maximizing the 
potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo, Angew. Chem. Int. Ed. 
Engl. 51 (2012) 8529-8533. 
[25] G. Caracciolo, H. Amenitsch, Cationic liposome/DNA complexes: from structure to 
interactions with cellular membranes, Eur. Biophys. J. 41 (2012) 815-829. 
[26] Z. Rezvani Amin, M. Rahimizadeh, H. Eshghi, A. Dehshahri, M. Ramezani, The effect of 
cationic charge density change on transfection efficiency of polyethylenimine, Iran. J. Basic 
Med. Sci. 16 (2013) 150-156. 
[27] G. Caracciolo, R. Caminiti, M.A. Digman, E. Gratton, S. Sanchez, Efficient escape from 
endosomes determines the superior efficiency of multicomponent lipoplexes, J. Phys. Chem. B 
113 (2009) 4995-4997. 
[28] S.E. Gratton, P.A. Ropp, P.D. Pohlhaus, J.C. Luft, V.J. Madden, M.E. Napier, et al., The 
effect of particle design on cellular internalization pathways, Proc. Natl. Acad. Sci. U. S. A. 105 
(2008) 11613-11618. 
[29] B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, J.P. Benoit, Physico-chemical stability of 
colloidal lipid particles, Biomaterials 24 (2003) 4283-4300. 
[30] J. Rejman, V. Oberle, I.S. Zuhorn, D. Hoekstra, Size-dependent internalization of particles 
via the pathways of clathrin- and caveolae-mediated endocytosis, Biochem. J. 377 (2004) 159-
169. 
[31] N.C. Stellwagen, E. Stellwagen, Effect of the matrix on DNA electrophoretic mobility, J. 
Chromatogr. A 1216 (2009) 1917-1929. 
[32] K. Takeuchi, M. Ishihara, C. Kawaura, M. Noji, T. Furuno, M. Nakanishi, Effect of zeta 
potential of cationic liposomes containing cationic cholesterol derivatives on gene 
transfection, FEBS Lett. 397 (1996) 207-209. 
[33] T. Fujiwara, S. Hasegawa, N. Hirashima, M. Nakanishi, T. Ohwada, Gene transfection 
activities of amphiphilic steroidepolyamine conjugates, Biochimica Biophysica Acta BBA 
Biomembr. 1468 (2000) 396-402. 
[34] D. Karra, R. Dahm, Transfection techniques for neuronal cells, J. Neurosci. 30 (2010) 6171-
6177. 
[35] O. Paecharoenchai, N. Niyomtham, A. Apirakaramwong, T. Ngawhirunpat, T. Rojanarata, 
B.E. Yingyongnarongkul, et al., Structure relationship of cationic lipids on gene transfection 
mediated by cationic liposomes, AAPS PharmSci- Tech 13 (2012) 1302-1308. 
[36] S.K. Sohaebuddin, P.T. Thevenot, D. Baker, J.W. Eaton, L. Tang, Nanomaterial cytotoxicity 
is composition, size, and cell type dependent, Part Fibre Toxicol. 7 (2010), 22-8977-7-22. 
[37] B. Martin, M. Sainlos, A. Aissaoui, N. Oudrhiri, M. Hauchecorne, J.P. Vigneron, et al., The 
design of cationic lipids for gene delivery, Curr. Pharm. Des. 11 (2005) 375-394. 
[38] D. Pozzi, C. Marchini, F. Cardarelli, F. Salomone, S. Coppola, M. Montani, et al., 
Mechanistic evaluation of the transfection barriers involved in lipid-mediated gene delivery: 
interplay between nanostructure and composition, Biochim. Biophys. Acta 1838 (2014) 957-
967. 
[39] S.C. Semple, A. Akinc, J. Chen, A.P. Sandhu, B.L. Mui, C.K. Cho, et al., Rational design of 
cationic lipids for siRNA delivery, Nat. Biotechnol. 28 (2010) 172-176. 
[40] S.M. Conley, M.I. Naash, Nanoparticles for retinal gene therapy, Prog. Retin. Eye Res. 29 
(2010) 376-397. 
[41] P. Dureau, L. Legat, M. Neuner-Jehle, S. Bonnel, S. Pecqueur, M. Abitbol, et al., 
Quantitative analysis of subretinal injections in the rat, Graefes Arch. Clin. Exp. Ophthalmol. 
238 (2000) 608-614. 
[42] J. Bennett, M. Ashtari, J. Wellman, K.A. Marshall, L.L. Cyckowski, D.C. Chung, et al., AAV2 
gene therapy readministration in three adults with congenital blindness, Sci. Transl. Med. 4 
(2012), 120ra15. 
[43] G.P. Ochoa, J.Z. Sesma, M.A. Diez, A. Diaz-Tahoces, M. Aviles-Trigeros, S. Grijalvo, et al., A 
novel formulation based on 2,3-di(tetradecyloxy)propan- 1-amine cationic lipid combined with 
polysorbate 80 for efficient gene delivery to the retina, Pharm. Res. 31 (2014) 1665-1675. 
[44] L. Peeters, N.N. Sanders, K. Braeckmans, K. Boussery, J. Van de Voorde, S.C. De Smedt, et 
al., Vitreous: a barrier to nonviral ocular gene therapy, Investig. Ophthalmol. Vis. Sci. 46 (2005) 
3553-3561. 
[45] X. Liu, C.A. Rasmussen, B.T. Gabelt, C.R. Brandt, P.L. Kaufman, Gene therapy targeting 
glaucoma: where are we? Surv. Ophthalmol. 54 (2009) 472-486. 
[46] S. Kugler, E. Kilic, M. Bahr, Human synapsin 1 gene promoter confers highly neuron-
specific long-term transgene expression from an adenoviral vector in the adult rat brain 
depending on the transduced area, Gene Ther. 10 (2003) 337-347. 
 
Supplementary data 
 
Scheme S1. Synthesis of glycerol-based cationic lipids (2, 4 and 5; lipid 1, 2 and 3, 
respectively) 
 
 
 
 
 
Reagents and Conditions. a and b [7]; c. i. Boc-NH-Gly3-COOH, EDC, NHS, CH2Cl2, 
overnight, r.t.; ii. 2, DIEA, DMF, overnight, 60 ºC; d. i. CH2Cl2:TFA 10%, r.t.; ii. 
carbonate polymer, MeOH:AcOEt, 1h, r.t.; e. i. p-NO2Ph, THF: CH2Cl2 (1:1), 4h, r.t.; ii. 
dimethylamine derivative, DMF, overnight, r.t. 
 
 
 tert-butyl-N-[2-[[2-[[2-[2,3-di(tetradecoxy)propylamino]-2-oxo-ethyl]amino]-2-oxo-
ethyl]-amino]-2-oxo-ethyl]carbamate (3). Yield 70 %, 1H-NMR (400 MHz, CDCl3) ǧ 
7.00 (broad m, NH), 6.93 (broad m, NH), 6.41 (broad m, NH), 4.18 (broad s, NH), 4.00 
(d, J = 5.6 Hz, 2H; CH2), 3.92 (d, J = 5.5 Hz, 2H; CH2), 3.83 (d, J = 5.6 Hz, 2H; CH2), 
3.48 (m, 9H; 2 CH2-O; CH-N and 2 CH2-O), 1.54 (m, 4H; 2 CH2), 1.45 (s, 9H; 3 CH3-
C); 1.28 (m, 44H; alkyl chain), 0.88 (t, J = 6.7 Hz, 6H; 2 CH3); 13C-NMR (125 MHz, 
CDCl3) ǧ 171.5 (CO), 170.2 (CO), 168.9 (CO), 168.4 (CO), 80.7 (C-O), 71.8 (CH2-O), 
71.2 (CH2-O), 70.2 (CH2-O), 53.4 (CH2-N), 42.9 (CH2-N), 42.8 (CH2-N), 40.9 (CH-N), 
31.9 (CH3-C), 29.9, 29.7, 29.6, 29.6, 29.6, 29.4, 29.3, 29.2, 26.1, 26.0, 25.4, 22.6, (alkyl 
chain) 14.0 (CH3-C); ESI-MS for C42H82N4O7 m/z 755.6183 (calculated) 755.6185 
(M+H)+. 
 
 
 
 
 
 
 2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-N-[2,3-di(tetradecoxy)propyl]acetamide (4, 
cationic lipid 2). Yield 87%, 1H-NMR (400 MHz, MeOD:CDCl3) ǧ 3.96 (s, 2H; CH2-
N), 3.86 (s, 2H; CH2-N), 3.71 (s, 2H; CH2-N), 3.55 (m, 4H; 2 CH2-O), 3.45 (m, 3H; 
CH2O and CH-NH), 1.55 (m, 2H; CH2-C), 1.37 (m, 6H; alkyl chain), 1.27 (m, 38H; 
alkyl chain), 0.88 (t, J = 7.1 Hz, 6H; 2 CH3); ESI-MS for C37H74N4O5 m/z 655.5659 
(calculated) 655.5658 (M+H)+ (found). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1-(2-dimethylaminoethyl)-3-[2,3-di(tetradecoxy)propyl]urea (5, cationic lipid 3). Yield 
65%; 1H -NMR (400 MHz, CDCl3) ǧ 3.44 (m, 6H; 3 CH2-O); 3.26 (m, 3H; CH-N and 
CH2-O); 2.46 (m, 4H; N-CH2-CH2-N), 2.28 (s, 3H; N-CH3), 2.25 (s, 3H; N-CH3), 1.55 
(m,. 2H; CH2-CH2), 1.25 (m, 46H; alkyl chain); 0.88 (t, J = 6.7 Hz; 6H; 2 CH3); 13C-
NMR (125 MHz, CDCl3) ǧ 161.1 (CO); 158.6 (CO), 71.7 (CH2-O), 70.2 (CH2-O), 58.8 
(CH2-O), 57.5 (CH-O), 45.0 (CH3-N), 41.9 (CO-CH2-N), 37.7 (CH2-N), 35.2 (CH2-N), 
31.8 (CH2-N), 30.0, 29.7, 29.6, 29.4, 29.3, 26.1, 22.6 (alkyl chain), 14.0 (CH3); ESI-MS 
for C31H65NO2 m/z 598.5808 (calculated) 598.5806 (M+H)+ (found). 
 
 
 
 
 
 
 
 
  
 
 
 
Figure S1. In vitro transfection of PECC cells with nioplexes based on cationic lipid 3 at 
30/1 cationic lipid/DNA (w/w) ratio. A) Shows direct fluorescence signal of EGFP 
(green) expression in non-identified cerebral cortical cells. Cell nuclei are marked in 
blue (Hoechst). B) Shows double labeling with Hoechst (blue) and GFAP (red). 
Transfected cells show green fluorescence from EGFP expression.  
 
 
 
 
 
  
Figure S2. Flow cytometry histograms of transfected cells with nioplexes based on 
cationic lipid 1, 2 and 3 in HEK-293, ARPE-19 and PECC cells at different cationic 
lipid/DNA (w/w) ratios. Color code: Black) control cells, Blue) 10/1 cationic lipid/DNA 
(w/w) ratio, Yellow) 20/1 cationic lipid/DNA (w/w) ratio and Green) 30/1 cationic 
lipid/DNA (w/w) ratio. (For interpretation of the references to color in this figure 
legend, the reader is referred to the web version of the article).  
 
 
 
 
 
 
